Clinical trials: Age Related Maculopathy
Age-related Macular Degeneration
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
The study will evaluate the efficacy and safety of two different regimens of Conbercept (Treat-and-Extend (T\&E) Regimen vs. Pro Re Nata (PRN)) in patients with wet AMD.
- Trial name
- NCT02802657
- Testing
- Treat-and-Extend regimen, Pro Re Nata, Conbercept
- Where
- 5 sites in China
- Volunteers
- 141 people
- Sponsor
- Xiaodong Sun
Epiretinal Membrane, Macular Holes
Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen
Surgical outcome of patients with macular drusen and co-existing abnormalities of the vitreoretinal interface, who routinely undergo pars plana vitrectomy with membrane peeling, is evaluated.
- Conditions
- Epiretinal Membrane, Macular Holes, Age Related Macular Degeneration
- Trial name
- NCT03927430
- Testing
- pars plana vitrectomy with membrane peeling
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Klinikum Chemnitz gGmbH
Macular Degeneration
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00259753
- Testing
- Bevasiranib
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- OPKO Health, Inc.
Diabetic Retinopathy, Age-Related Macular Degeneration
Validation of Bulbicam for DR- and AMD-patients
Aim To investigate repeatability and stability of the six OTH-related Bulbicam tests in patients suffering from a) Diabetic retinopathy (DR), b) Age related macular degeneration (AMD) and matched healthy controls (HC).
- Trial name
- NCT05441072
- Testing
- BulbiCam
- Where
- Norway
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Meddoc
Age-related Macular Degeneration
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
- Trial name
- NCT04151212
- Testing
- BAT5906 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Bio-Thera Solutions
Macular Degeneration
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
The objective of this study is to evaluate the effects of 2 intravitreal injections with Ranibizumab or Avastin on endothelial function in subjects with neovascular macular degeneration compared to patients with dry AMD.
- Trial name
- NCT00727753
- Testing
- Ranibizumab, Bevacizumab, No treatment
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- University of Zurich
AMD
the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration
To evaluate the status of the blood-aqueous barrier by objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP) in patients with exudative age-related macular degeneration (AMD)…
- Trial name
- BABAMD (NCT07375901)
- Testing
- laser flare photometry before intravitreal injection
- Where
- Ukraine
- Volunteers
- 30 people
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
Intraocular Inflammation, Retinal Vascular Occlusion
Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
This non-interventional descriptive study was undertaken to better understand the most common imaging features associated with inflammation arising in the post-marketing setting when brolucizumab was prescribed in routine…
- Trial name
- NCT05657158
- Testing
- Brolucizumab
- Where
- Switzerland
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration, nAMD
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks…
- Trial name
- HUTONG (NCT05562947)
- Testing
- PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL)
- Where
- 14 sites in China
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration
Combined Therapy in Age-Related Macular Degeneration (ARMD)
The purpose of this study is to investigate the efficacy of combined intravitreal therapy with or without prior photodynamic therapy in patients with wet age-related macular degeneration (AMD).
- Trial name
- NCT00805649
- Testing
- Low fluorescence Photodynamic therapy, core pars plana vitrectomy, dexamethasone
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD
This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.
- Trial name
- AURORA (NCT01157715)
- Testing
- intravitreal injection of KH902
- Where
- 9 sites in China
- Volunteers
- 122 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Geographic Atrophy
A Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- CATALINA (NCT04465955)
- Testing
- NGM621
- Where
- 65 sites in United States
- Volunteers
- 320 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Age-Related Macular Degeneration
OKKO Health Hyperacuity, Contrast and Colour Game Validation in Age-related Macular Degeneration
Smartphone apps have the potential to measure standard metrics of visual function. In addition, new tests may serve as digital biomarkers to detect early progression of disease, assess risk of developing disease or expand the…
- Trial name
- NCT05569226
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- OKKO Health
Dry Macular Degeneration
BioCurrent Electrical Stimulation for the Treatment of Dry ARMD
This study evaluates the treatment of Dry Macular Degeneration and the resulting change in vision with a very, very low current that is similar to what occurs in the body naturally.
- Trial name
- NCT02699216
- Testing
- Electrical Stimulation of the Retina
- Volunteers
- healthy volunteers welcome
- Sponsor
- DuBois Vision Clinic
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Macular Degeneration, Retinal Drusen
Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen.
- Trial name
- NCT02569892
- Testing
- Pascal Retinal Laser Photocoagulator
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Stanford University
Macular Degeneration
VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents
The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration.
- Trial name
- NCT01655589
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Institute of Vision, Brasil
Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve
Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries.
- Trial name
- NCT06890026
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Denmark
- Volunteers
- 742 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Neovascular Age-related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301…
- Trial name
- NCT03386474
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Age Related, Geographic Atrophy
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy.
- Trial name
- COCO-GA (NCT05961332)
- Testing
- Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.